Novartis's Scemblix Drug Meets Main Goals in Late-Stage Leukemia Trial
08 Janvier 2024 - 8:01AM
Dow Jones News
By Adria Calatayud
Novartis said its Scemblix drug met its primary goals in a
late-stage clinical trial for newly diagnosed patients with chronic
myeloid leukemia.
The Swiss pharmaceutical company said Monday that Scemblix
showed superior major molecular response compared to approved
standard-of-care treatments that known as tyrosine kinase
inhibitors--a type of targeted therapy--at week 48 of
treatment.
Scemblix also demonstrated a favorable safety and tolerability
profile with fewer adverse events and treatment discontinuations
relative to the standard of care, Novartis said.
The company said the trial continues and that it will release
new data evaluating patients' major molecular response after 96
weeks of treatment, the key secondary goal of the trial, as well as
other secondary objectives.
Details will be presented at an upcoming medical conference and
included as part of regulatory submissions in 2024, Novartis
said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
January 08, 2024 01:46 ET (06:46 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Novartis (NYSE:NVS)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
